149367-83-9

Basic information

• Product Name: 2H-Benzimidazole-2-thione,1,3-dihydro-4-methoxy-(9CI)
• Synonyms: 2H-Benzimidazole-2-thione,1,3-dihydro-4-methoxy-(9CI);4-METHOXY-1H-BENZO[D]IMIDAZOLE-2(3H)-THIONE
• CAS NO: 149367-83-9
• Molecular Formula: C₈H₈N₂OS
• Molecular Weight: 180.23
• Product Categories: BENZIMIDAZOLE
• Mol File: 149367-83-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2H-Benzimidazole-2-thione,1,3-dihydro-4-methoxy-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Benzimidazole-2-thione,1,3-dihydro-4-methoxy-(9CI)(149367-83-9)
• EPA Substance Registry System: 2H-Benzimidazole-2-thione,1,3-dihydro-4-methoxy-(9CI)(149367-83-9)

Safety Data

• Hazardous Substances Data: 149367-83-9(Hazardous Substances Data)

Usage

Composition

Contains sulfur, oxygen, nitrogen atoms

Structure

Heterocyclic compound

Pharmaceutical Properties

Potential pharmaceutical applications

Biological Activities

Anticancer, antiviral, antimicrobial properties

Significance

Subject of interest for drug development and research

Potential Applications

Medicinal chemistry, pharmaceutical industry

Upstream product

• 16554-45-3 2-methoxy-6-nitroaniline 
• 75-15-0 carbon disulfide 
• 37466-89-0 3-methoxybenzene-1,2-diamine 

Relevant articles and documents

Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization

PRMT5 plays important roles in diverse cellular processes and is upregulated in several human malignancies. Besides, PRMT5 has been validated as an anticancer target in mantle cell lymphoma. In this study, we found a potent and selective PRMT5 inhibitor by performing structure-based virtual screening and hit optimization. The identified compound 17 (IC50 = 0.33 μM) exhibited a broad selectivity against a panel of other methyltransferases. The direct binding of 17 to PRMT5 was validated by surface plasmon resonance experiments, with a Kd of 0.987 μM. Kinetic experiments indicated that 17 was a SAM competitive inhibitor other than the substrate. In addition, 17 showed selective antiproliferative effects against MV4-11 cells, and further studies indicated that the mechanism of cellular antitumor activity was due to the inhibition of PRMT5 mediated SmD3 methylation. 17 may represent a promising lead compound to understand more about PRMT5 and potentially assist the development of treatments for leukemia indications.